Rheumatology Network's Top 5: April 23, 2022


Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 23, 2022.

Rheumatoid Arthritis Quiz: DMARDs and Immune Response to COVID-19 Vaccination

COVID-19 vaccines and drugs for rheumatoid arthritis (RA) don’t always mix well. How much do you know about how RA medications impact the immune response generated by COVID-19 vaccines?

Strict Treat-to-Target Approach Beneficial for Patients With RA

White a treat-to-target strategy is an important part of managing patients with rheumatoid arthritis, a more controlled implementation with closer follow-up appointments and patient education yielded better outcomes.

Belimumab Shows Favorable Long-Term Disease Control in Patients With SLE

Until now, there has been limited information on the long-term safety and efficacy of belimumab in Chinese patients with systemic lupus erythematosus.

Severe Flares in Patients With SLE Linked to Poorer Quality of Life

Disease flares in systemic lupus erythematosus are associated with damage. However, the impact of flares on health-related quality of life have not been analyzed.

Treatment With bDMARDs Improves Quality of Life in Patients With PsA

As quality of life (QoL) in patients with psoriatic arthritis (PsA) is significantly lower when compared with patients with psoriasis, one of the main goals of treating PsA is improving QoL.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
© 2024 MJH Life Sciences

All rights reserved.